XML 41 R26.htm IDEA: XBRL DOCUMENT v3.25.1

REVENUES (Tables)

3 Months Ended

Mar. 31, 2025

Revenue from Contract with Customer [Abstract]

Summary of Total Revenues

The following table summarizes our Total revenues:

						Three Months Ended March 31, 2025																								Three Months Ended March 31, 2024
(in millions)						U.S.						Europe						Rest of World						Total						U.S.						Europe						Rest of World						Total
Product sales:
HIV
Biktarvy						$	2,474					$	375					$	301					$	3,150					$	2,315					$	365					$	265					$	2,946
Descovy						538						21						27						586						371						26						29						426
Genvoya						305						40						19						364						332						49						21						403
Odefsey						215						57						10						281						223						76						11						310
Symtuza - Revenue share(1)						82						29						3						114						104						33						3						141
Other HIV(2)						50						31						10						91						60						45						12						117
Total HIV						3,664						553						370						4,587						3,405						596						342						4,342
Liver Disease
Sofosbuvir/Velpatasvir(3)						166						80						99						346						248						79						78						405
Vemlidy						100						12						140						252						95						11						119						225
Other Liver Disease(4)						68						76						17						161						42						47						19						107
Total Liver Disease						335						168						256						758						385						137						215						737
Veklury						199						22						82						302						315						70						169						555
Oncology
Cell Therapy
Tecartus						40						31						8						78						55						36						8						100
Yescarta						160						149						77						386						170						158						52						380
Total Cell Therapy						200						180						84						464						225						195						60						480
Trodelvy						181						75						37						293						206						68						36						309
Total Oncology						381						255						121						757						431						262						96						789
Other
AmBisome						5						67						66						139						14						70						60						144
Other(5)						47						9						14						70						59						9						12						80
Total Other						52						76						81						209						73						79						71						224
Total product sales						4,631						1,073						909						6,613						4,609						1,144						894						6,647
Royalty, contract and other revenues						37						11						6						54						23						15						1						39
Total revenues						$	4,668					$	1,084					$	915					$	6,667					$	4,633					$	1,159					$	894					$	6,686

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”).

(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.

(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).

(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Livdelzi/Lyvdelzi, Sovaldi, Viread and Vosevi.

(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.

Summary of Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior years:

						Three Months Ended
						March 31,
(in millions)						2025						2024
Revenue share with Janssen Ireland and royalties for licenses of intellectual property						$	157					$	171
Changes in estimates						$	214					$	160

Summary of Contract Balances

The following table summarizes our contract balances:

(in millions)						March 31, 2025						December 31, 2024
Contract assets						$	304					$	277
Contract liabilities(1)						$	56					$	58

_______________________________

(1)    Future revenues recognized from contract liabilities are not expected to be material in any one year.

X

- Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

+ Details

Name:	us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-SubTopic 10
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-13

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration